Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koh, Eun Sil | - |
dc.contributor.author | Han, Kyungdo | - |
dc.contributor.author | Nam, You-Seon | - |
dc.contributor.author | Wittbrodt, Eric T. | - |
dc.contributor.author | Fenici, Peter | - |
dc.contributor.author | Kosiborod, Mikhail N. | - |
dc.contributor.author | Heerspink, Hiddo J. L. | - |
dc.contributor.author | Yoo, Soon-Jib | - |
dc.contributor.author | Kwon, Hyuk-Sang | - |
dc.date.available | 2021-03-04T00:40:23Z | - |
dc.date.created | 2021-03-04 | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.uri | http://scholarworks.bwise.kr/ssu/handle/2018.sw.ssu/40346 | - |
dc.description.abstract | Aims To investigate the effectiveness of sodium-glucose co-transporter-2 (SGLT2) inhibitors on the risk of progression to end-stage renal disease (ESRD) and all-cause mortality in a broad range of patients with type 2 diabetes (T2D) using a Korean nationwide cohort. Materials and Methods Using data from the Korean National Health Insurance Service database from January 2014 to December 2017, a total of 701 674 patients were identified with T2D. We divided these patients into new users of SGLT2 inhibitors and new users of other glucose-lowering drugs (oGLDs). Using propensity scores, patients in the two groups were matched 1:1. We assessed the risk of ESRD and all-cause death. Results There were 45 016 patients in each group, and baseline characteristics were well balanced between the groups. The patients' mean age was 58.1 +/- 10.6 years and mean estimated glomerular filtration rate (eGFR) was 89.2 +/- 27.4 mL/min/1.73m(2), and 8% of patients had proteinuria. We identified 167 incident ESRD cases and 1070 all-cause deaths during follow-up. Use of SGLT2 inhibitors versus oGLDs was associated with a lower risk of ESRD (hazard ratio [HR] 0.47, 95% confidence interval [CI] 0.34 to 0.65) and all-cause death (HR 0.82, 95% CI 0.73 to 0.93). In a subgroup analysis by eGFR, initiation of SGLT2 inhibitor treatment, compared with oGLD treatment, was associated with lower risk of progression to ESRD among patients with eGFR 60 to 90 mL/min/1.73m(2) and those with eGFR < 60 mL/min/1.73m(2), and a lower risk of all-cause death was associated with SGLT2 inhibitors versus oGLDs in patients with eGFR >= 90 and 60 to 90 mL/min/1.73m(2). Conclusion In this large nationwide study of Korean patients with T2D, initiation of SGLT2 inhibitors versus oGLDs was associated with lower risk of ESRD and all-cause death. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.relation.isPartOf | DIABETES OBESITY & METABOLISM | - |
dc.title | Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea) | - |
dc.type | Article | - |
dc.identifier.doi | 10.1111/dom.14239 | - |
dc.type.rims | ART | - |
dc.identifier.bibliographicCitation | DIABETES OBESITY & METABOLISM, v.23, no.2, pp.455 - 466 | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000591702300001 | - |
dc.identifier.scopusid | 2-s2.0-85096710056 | - |
dc.citation.endPage | 466 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 455 | - |
dc.citation.title | DIABETES OBESITY & METABOLISM | - |
dc.citation.volume | 23 | - |
dc.contributor.affiliatedAuthor | Han, Kyungdo | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.subject.keywordAuthor | all& | - |
dc.subject.keywordAuthor | #8208 | - |
dc.subject.keywordAuthor | cause death | - |
dc.subject.keywordAuthor | ESRD | - |
dc.subject.keywordAuthor | SGLT& | - |
dc.subject.keywordAuthor | #8208 | - |
dc.subject.keywordAuthor | 2 inhibitor | - |
dc.subject.keywordPlus | COTRANSPORTER 2 INHIBITORS | - |
dc.subject.keywordPlus | SGLT2 INHIBITORS | - |
dc.subject.keywordPlus | DIABETES-MELLITUS | - |
dc.subject.keywordPlus | KIDNEY-DISEASE | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | EMPAGLIFLOZIN | - |
dc.subject.keywordPlus | DAPAGLIFLOZIN | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordPlus | FAILURE | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Soongsil University Library 369 Sangdo-Ro, Dongjak-Gu, Seoul, Korea (06978)02-820-0733
COPYRIGHT ⓒ SOONGSIL UNIVERSITY, ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.